Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by 1998novlon Oct 16, 2020 8:08pm
234 Views
Post# 31733108

Overreaction

Overreaction I think many here would make great executives and would do great investor relations work. Unfortunately as a shareholder, you've allocated that responsibility to the company. You can vote your shares and even become an activist if you have enough shares.  As a shareholder you are not entitled to the whole story, in fact you are only entitled to public information. If you get non public information you are locked out from trading the stock. As much as I would like a prefect message from the company, I would prefer them to execute in getting another drug approved with the FDA, which they have been successful at before. So either trust them and keep your shares or don't and sell them - but to bombard them for not being perfect in answering questions around non public information isn't fair. They have improved communication extremely well since the end of last year and are allocating resources to improving in that arena, that part is clear to me. Also, today's addition of the Molson family is likely the largest endorsement in credibility one could ask for, but I'm sure it's not good enough to those on this board that are short term focused on next weeks share price..., patience folks!!
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse